BACKGROUND: Omacetaxine, a protein synthesis inhibitor, is indicated in the United States for the treatment of patients with chronic-phase (CP) or accelerated-phase (AP) chronic myeloid leukemia (CML) with resistance and/or intolerance to 2 or more tyrosine kinase inhibitors. METHODS: The final analysis, with 24 months of follow-up, included additional efficacy and safety analyses to assess the benefit of long-term omacetaxine administration (1.25 mg/m(2) twice daily for 14 days every 28 days followed by 7 days every 28 days) in CP-CML and AP-CML patients receiving >3 cycles. RESULTS: Eighteen percent of CP-CML patients achieved a major cytogenetic response (MCyR) with a median duration of 12.5 months (95% confidence interval [CI], 3.5 months to not reached [NR]); responses were maintained for ≥12 months in 3 of 14 responders, and the median overall survival (OS) was 40.3 months (95% CI, 23.8 months to NR). Among patients with AP-CML, 14% achieved or maintained a major hematologic response for a median of 4.7 months (95% CI, 3.6 months to NR); MCyR was not achieved, and the median OS was 14.3 months (95% CI, 6.7-18.7 months). In patients with CP-CML and patients with AP-CML who received >3 cycles of treatment (n = 50 and n = 14, respectively), the median OS was 49.3 months (95% CI, 23.8 months to NR) and 24.6 months (95% CI, 12-37.2 months), respectively. Grade 3 or higher hematologic toxicities were the major side effects (79% and 73% for CP-CML and AP-CML, respectively), with discontinuation due to toxicity in 10% of CP patients and in 5% of AP patients. CONCLUSIONS: These results suggest that the long-term administration of omacetaxine is feasible with dose adjustments to manage toxicities and that omacetaxine provides a durable benefit for some patients.
BACKGROUND:Omacetaxine, a protein synthesis inhibitor, is indicated in the United States for the treatment of patients with chronic-phase (CP) or accelerated-phase (AP) chronic myeloid leukemia (CML) with resistance and/or intolerance to 2 or more tyrosine kinase inhibitors. METHODS: The final analysis, with 24 months of follow-up, included additional efficacy and safety analyses to assess the benefit of long-term omacetaxine administration (1.25 mg/m(2) twice daily for 14 days every 28 days followed by 7 days every 28 days) in CP-CML and AP-CMLpatients receiving >3 cycles. RESULTS: Eighteen percent of CP-CMLpatients achieved a major cytogenetic response (MCyR) with a median duration of 12.5 months (95% confidence interval [CI], 3.5 months to not reached [NR]); responses were maintained for ≥12 months in 3 of 14 responders, and the median overall survival (OS) was 40.3 months (95% CI, 23.8 months to NR). Among patients with AP-CML, 14% achieved or maintained a major hematologic response for a median of 4.7 months (95% CI, 3.6 months to NR); MCyR was not achieved, and the median OS was 14.3 months (95% CI, 6.7-18.7 months). In patients with CP-CML and patients with AP-CML who received >3 cycles of treatment (n = 50 and n = 14, respectively), the median OS was 49.3 months (95% CI, 23.8 months to NR) and 24.6 months (95% CI, 12-37.2 months), respectively. Grade 3 or higher hematologic toxicities were the major side effects (79% and 73% for CP-CML and AP-CML, respectively), with discontinuation due to toxicity in 10% of CPpatients and in 5% of AP patients. CONCLUSIONS: These results suggest that the long-term administration of omacetaxine is feasible with dose adjustments to manage toxicities and that omacetaxine provides a durable benefit for some patients.
Authors: R M Tujebajeva; D M Graifer; N B Matasova; O S Fedorova; V B Odintsov; N A Ajtkhozhina; G G Karpova Journal: Biochim Biophys Acta Date: 1992-01-06
Authors: Jorge E Cortes; Franck E Nicolini; Meir Wetzler; Jeffrey H Lipton; Luke Akard; Adam Craig; Nisha Nanda; Annie-Claude Benichou; Janis Leonoudakis; H Jean Khoury; Andreas Hochhaus; Michele Baccarani; Hagop M Kantarjian Journal: Clin Lymphoma Myeloma Leuk Date: 2013-06-17
Authors: H Jean Khoury; Jorge E Cortes; Hagop M Kantarjian; Carlo Gambacorti-Passerini; Michele Baccarani; Dong-Wook Kim; Andrey Zaritskey; Athena Countouriotis; Nadine Besson; Eric Leip; Virginia Kelly; Tim H Brümmendorf Journal: Blood Date: 2012-02-27 Impact factor: 22.113
Authors: Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: Natalya Beglyarova; Eugenia Banina; Yan Zhou; Ramilia Mukhamadeeva; Grigorii Andrianov; Egor Bobrov; Elena Lysenko; Natalya Skobeleva; Linara Gabitova; Diana Restifo; Max Pressman; Ilya G Serebriiskii; John P Hoffman; Keren Paz; Diana Behrens; Vladimir Khazak; Sandra A Jablonski; Erica A Golemis; Louis M Weiner; Igor Astsaturov Journal: Clin Cancer Res Date: 2016-07-06 Impact factor: 12.531
Authors: Thomas P Howard; Elaine M Oberlick; Matthew G Rees; Taylor E Arnoff; Minh-Tam Pham; Lisa Brenan; Mariana DoCarmo; Andrew L Hong; Guillaume Kugener; Hsien-Chao Chou; Yiannis Drosos; Kaeli M Mathias; Pilar Ramos; Brinton Seashore-Ludlow; Andrew O Giacomelli; Xiaofeng Wang; Burgess B Freeman; Kaley Blankenship; Lauren Hoffmann; Hong L Tiv; Prafulla C Gokhale; Cory M Johannessen; Elizabeth A Stewart; Stuart L Schreiber; William C Hahn; Charles W M Roberts Journal: Clin Cancer Res Date: 2020-07-06 Impact factor: 12.531
Authors: Zachary J Walker; Beau M Idler; Lorraine N Davis; Brett M Stevens; Michael J VanWyngarden; Denis Ohlstrom; Shelby C Bearrows; Andrew Hammes; Clayton A Smith; Craig T Jordan; Tomer M Mark; Peter A Forsberg; Daniel W Sherbenou Journal: Clin Cancer Res Date: 2020-10-27 Impact factor: 13.801